RXRX RECURSION PHARMACEUTICALS INC

Altitude Lab Relocates to Gateway’s BioHive Hub

Altitude Lab Relocates to Gateway’s BioHive Hub

Altitude’s new facility will be housed within Recursion’s expanded headquarters and will promote increased collaboration in Downtown Salt Lake City’s rapidly growing biotech innovation ecosystem.

SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) -- announced today that its incubator program and facility will leave Research Park to grow its operation in the Gateway’s BioHive hub as part of Recursion’s recently expanded headquarters. The health care incubator will join biotechs Recursion and Perfect Day in the new location in June 2023.

Launched in 2020, Altitude Lab was founded to help build a robust life sciences ecosystem in Salt Lake City by supporting early-stage startups and historically underrepresented founders. Altitude Lab, which is operated by The Recursion Foundation, has incubated 17 startups to date. These rapidly growing companies have successfully .

“In our new facility, Altitude Lab continues to reduce barriers to entrepreneurship and increase racial and gender representation in health care innovation. Vestar has been a great partner to help us get our new location up and running quickly. We are now rapidly scaling our entrepreneurial resources, lab facility, and ability to connect our community and investor network to accelerate Utah’s health care economy,” said Chandana Haque, executive director of Altitude Lab. 

The new facility will provide over 15,000 square feet of incubation space which includes shared and private labs, tissue culture facilities, over $1M in molecular and cell biology tools, and extensive site services to manage equipment and train resident scientists. In an effort to build more scientific connection, Recursion has extended use of its cafeteria to resident startups. 

“We launched Altitude Lab to help build a critical mass of biotech and health care innovation in Utah,” said Chris Gibson, Ph.D., Co-founder and CEO at Recursion. “Other leading geographies across the country, like San Francisco and Kendall Square, purposefully build spaces for scientists from many companies to congregate. Recursion is proud to be able to host more scientists in our own space to encourage this kind of collaboration and exchange of ideas. It’s an early model for the kind of supportive community we envision for Utah’s life science sector.”

Altitude Lab's new location at The Gateway’s BioHive Hub will also provide easy access to public transportation and various dining options to support social and networking events. In addition, the new space design fosters creativity and closer collaboration, focusing on providing a comfortable, modern, and centrally accessible workspace for founders.

This year, Altitude Lab graduated five companies from its program, including Teiko Bio, 3Helix, Nexeos Bio, Peel Therapeutics, and Rebel Medicine. Peel Therapeutics and Rebel Medicine plan to continue operating in private labs within Altitude’s new facility.

“Incubating at Altitude Lab helped Peel to meet scientific milestones, recruit board members, and build deeper relationships in the scientific community. Now, the private lab offering fills a much needed gap in Utah’s current real estate market. By offering additional private space to graduating companies, Altitude is enabling our biotech to scale its operation while minimizing build out costs and construction delays. We are thrilled to continue our growth alongside the Altitude community,” said Joshua Schiffman, MD, cofounder and chief executive officer of Peel Therapeutics. 

Altitude Lab is currently accepting applications. For more information about Altitude Lab visit . To register for the Fall Open House, .

About Altitude Lab

Altitude Lab is building a new, representative generation of founders to seed the next cycle of health care innovation in Utah's . Currently located in University of Utah Research Park, Altitude Lab is an incubator focused on early stage life science and health care companies. The initiative is part of a and from to foster socially-responsible entrepreneurship, job creation, and economic productivity. The Recursion Foundation, under which Altitude Lab operates, is a 501(c)(3) nonprofit organization.

Learn more at or connect on .

About Recursion

is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of , the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at , or connect on and .



Ryan Kelly
Recursion
 
EN
25/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE

Recursion Reports Grant of Inducement Awards as Permitted by the Nasda...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award w...

 PRESS RELEASE

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management will also participate in the following upcoming investor conference: 28th Annual Needham Growth Conference - Friday, January 16, 2026 Webcasts may be found in th...

 PRESS RELEASE

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonst...

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baselineNatural history analysis showed that 87% of unt...

 PRESS RELEASE

Recursion Announces Webinar For Upcoming Clinical Data Readout on the ...

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recurs...

 PRESS RELEASE

Recursion Reports Third Quarter 2025 Financial Results and Provides Bu...

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseasesWith this achievement, Recursion will have reached over $500 million in milestone and upfront payments across all its partnerships and collaborationsApproximately $785 million of cash and cash equivalents (unaudited) as of October 9, 2025- runway through the end of 2027, without additional financing...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch